- Home
- SAMG vs MGNX Comparison
SAMG vs MGNX Comparison
Compare SAMG & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAMG
- MGNX
- Stock Information
- Founded
- SAMG 2002
- MGNX 2000
- Country
- SAMG United States
- MGNX United States
- Employees
- SAMG N/A
- MGNX N/A
- Industry
- SAMG Investment Managers
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- SAMG Finance
- MGNX Health Care
- Exchange
- SAMG Nasdaq
- MGNX Nasdaq
- Market Cap
- SAMG 155.5M
- MGNX 125.2M
- IPO Year
- SAMG 2013
- MGNX 2013
- Fundamental
- Price
- SAMG $16.54
- MGNX $1.22
- Analyst Decision
- SAMG
- MGNX Hold
- Analyst Count
- SAMG 0
- MGNX 10
- Target Price
- SAMG N/A
- MGNX $6.83
- AVG Volume (30 Days)
- SAMG 37.3K
- MGNX 750.7K
- Earning Date
- SAMG 03-06-2025
- MGNX 05-08-2025
- Dividend Yield
- SAMG 4.89%
- MGNX N/A
- EPS Growth
- SAMG 4.17
- MGNX N/A
- EPS
- SAMG 1.00
- MGNX N/A
- Revenue
- SAMG $123,651,000.00
- MGNX $149,962,000.00
- Revenue This Year
- SAMG $8.52
- MGNX N/A
- Revenue Next Year
- SAMG $3.95
- MGNX $25.32
- P/E Ratio
- SAMG $16.36
- MGNX N/A
- Revenue Growth
- SAMG 5.32
- MGNX 155.26
- 52 Week Low
- SAMG $13.93
- MGNX $1.17
- 52 Week High
- SAMG $19.20
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- SAMG 40.86
- MGNX 18.97
- Support Level
- SAMG $15.97
- MGNX $1.89
- Resistance Level
- SAMG $16.68
- MGNX $2.24
- Average True Range (ATR)
- SAMG 0.37
- MGNX 0.17
- MACD
- SAMG 0.02
- MGNX -0.08
- Stochastic Oscillator
- SAMG 43.51
- MGNX 4.02
About SAMG Silvercrest Asset Management Group Inc.
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).